Celgene dives 10% after ditching key drug
October 20, 2017 at 11:31 AM EDT
The once high-profile drug was expected to bring in as much as $2.4 billion in peak revenue.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.